Kategorien
Aktien

Laurus Labs Limited

SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.
INR
  • INR
  • INR
Mitarbeiter 5.304

Laurus Labs Limited outperformed den DAX um +569 % vom 20.12.2016 bis 27.08.2021

Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von

26 News & Informationen zur Laurus Labs Limited Aktie

  • Ahead of Market: 12 things that will decide stock action on Monday
    economictimes.indiatimes.com

    Ahead of Market: 12 things that will decide stock action on Monday

    Gaurav Ratnaparkhi of Sharekhan said a brief pause in market rally is a good sign as it would allow the overbought hourly momentum indicators to cool off and prepare for the next cycle on the upside.

  • Metals, IT lift Sensex by 123 pts; Airtel jumps 4%, SBI falls 3%
    economictimes.indiatimes.com

    Metals, IT lift Sensex by 123 pts; Airtel jumps 4%, SBI falls 3%

    Selling in broader markets kept investors on their toes. Metals, IT saw buying while banks were under pressure.

  • Laurus Labs Q1FY22 net profit surges 40% to Rs 241 crore, led by anti-HIV formulation sales
    moneycontrol.com

    Laurus Labs Q1FY22 net profit surges 40% to Rs 241 crore, led by anti-HIV formulation sales

    The earnings before interest, tax, depreciation and ammortisation (EBITDA) margins expanded 210 basis points YoY to 31.3 percent; however, on sequential basis (QoQ), Laurus' EBITDA margins were down by 250 basis points.

  • Sensex snaps 3-day winning run; Hindalco leaps 10%, Tata Steel 7%
    economictimes.indiatimes.com

    Sensex snaps 3-day winning run; Hindalco leaps 10%, Tata Steel 7%

    Asian markets were trading higher as China tried to assuage investors following the crackdown on technology companies. The Fed statement suggested that ongoing vaccinations were helping to support the economy, said an analyst.

  • Tatva Chintan, Glenmark Life Sciences IPO, Tech Mahindra, LIC Housing, IDBI Bank stocks in focus
    financialexpress.com

    Tatva Chintan, Glenmark Life Sciences IPO, Tech Mahindra, LIC Housing, IDBI Bank stocks in focus

    Nifty futures were trading 8.50 points up at 15,715.50 on Singaporean Exchange, signaling a tepid opening for BSE Sensex and Nifty 50 on Thursday

  • SGX Nifty down 10 points; here's what changed for market while you were sleeping
    economictimes.indiatimes.com

    SGX Nifty down 10 points; here's what changed for market while you were sleeping

    Asian shares markets opened higher on Thursday as investors took heart from gains in US high-tech shares after the Fed decided against any major changes to its monetary policy. MSCI's broadest index of Asia-Pacific shares outside Japan was up by 1.06 per cent.

  • Top 10 things to know before the market opens
    moneycontrol.com

    Top 10 things to know before the market opens

    Trends on SGX Nifty indicate a cautious opening for the index in India with a 8 points gain.

  • Buzzing Stocks: Tech Mahindra, Route Mobile, Jubilant Ingrevia and other stocks in news today
    moneycontrol.com

    Buzzing Stocks: Tech Mahindra, Route Mobile, Jubilant Ingrevia and other stocks in news today

    Stocks In the News: Check out the companies making the biggest headlines before the opening bell.

  • Glenmark Life Sciences IPO opens today, should you subscribe?
    moneycontrol.com

    Glenmark Life Sciences IPO opens today, should you subscribe?

    Glenmark Life Sciences IPO: The company has debt-to-equity of 1.3x with a debt of Rs 916 crore which includes Rs 800 crore payable to Glenmark Pharmaceuticals, post-IPO debt will be negligible.

  • Glenmark Life IPO opens next week; dates, price band announced
    economictimes.indiatimes.com

    Glenmark Life IPO opens next week; dates, price band announced

    At the higher end of the price band, the company is expected to raise Rs 1,513.6 crore via its initial shale sale. The promoter holds 100 per cent stake in the company.

  • Tatva Chintan IPO: Why it attracted the second-highest subscription level among issues in 2021
    moneycontrol.com

    Tatva Chintan IPO: Why it attracted the second-highest subscription level among issues in 2021

    Most companies are capitalising on suitable market conditions to raise equity capital at premium valuations. Tatva Chintan was no exception and investors bid for 180 times the shares that the company offered.

  • Glenmark Life Sciences IPO price band fixed at Rs 695-720, to raise Rs 1,513.6 crore
    moneycontrol.com

    Glenmark Life Sciences IPO price band fixed at Rs 695-720, to raise Rs 1,513.6 crore

    Glenmark Life IPO: The IPO comprises a fresh issue of Rs 1,060 crore and an offer for sale of 63 lakh equity shares by promoter Glenmark Pharmaceuticals

  • Buzzing Stocks: HCL Tech, Clean Science, GR Infraprojects and other stocks in news today
    moneycontrol.com

    Buzzing Stocks: HCL Tech, Clean Science, GR Infraprojects and other stocks in news today

    Stocks In News: Check out the companies making the biggest headlines before the opening bell.

  • Tatva Chintan Pharma Chem IPO opens tomorrow, 10 key things to know about the issue
    moneycontrol.com

    Tatva Chintan Pharma Chem IPO opens tomorrow, 10 key things to know about the issue

    Promoters held 1,61,75,850 equity shares in aggregate, representing 80.53 percent of total paid up equity of Tatva Chintan.

  • Stock Markets Live: Sensex, Nifty Open Higher; Infosys Swings After Q1 Earnings
    bloombergquint.com

    Stock Markets Live: Sensex, Nifty Open Higher; Infosys Swings After Q1 Earnings

    Infosys, L&T Technology, Tinplate, Craftsman Automation, Dodla Dairy may react as the companies reported quarterly results after the market closed Wednesday. Wipro, L&T Infotech, Cyient are among the companies scheduled to report earnings Thursday. Kalpataru Power, Laurus Labs among companies holding their annual shareholders’ meeting. India to release trade data for June. Foreign investors bought net Rs 69.91 crore of stocks on Tuesday, according to NSDL website.

  • Buy Laurus Labs; target of Rs 800: Motilal Oswal
    moneycontrol.com

    Buy Laurus Labs; target of Rs 800: Motilal Oswal

    Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 800 in its research report dated July 06, 2021.

  • 7 Small-Cap Stocks That Surged Over 10% In Trade Today
    goodreturns.in

    7 Small-Cap Stocks That Surged Over 10% In Trade Today

    As domestic equity markets began to rebound from the adverse environment observed in the latter week of June 2021, small-cap companies continued to outperform. The BSE SmallCap index continued to rise, reaching an all-time high of 25,809.26. The index increased by roughly 1%.

  • 3 Stocks To Buy According To Broking Firm Sharekhan
    goodreturns.in

    3 Stocks To Buy According To Broking Firm Sharekhan

    Broking firm Sharekhan has suggested buying the three stocks of UPL, Laurus and Sumitomo Chemicals for long-term investors. According to the brokerage firm, the three stocks have a reasonable upside target from the current levels and have the potential to generate good returns. Here are some of the reasons Sharekhan is suggesting to buy the shares of these three companies.

  • Laurus Labs gets licence to manufacture DRDO's anti-COVID drug 2DG
    businesstoday.in

    Laurus Labs gets licence to manufacture DRDO's anti-COVID drug 2DG

    2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing

  • Laurus Labs Receives Licence From DRDO To Manufacture And Market COVID Drug 2DG
    businessworld.in

    Laurus Labs Receives Licence From DRDO To Manufacture And Market COVID Drug 2DG

    Shares of Laurus Labs were trading at Rs 674.20 per scrip on BSE, up 1.08 per cent from the previous close., , laurus labs, government, shares, cdsco, Covid 19

  • Laurus Labs receives licence from DRDO to manufacture and market COVID drug 2DG
    economictimes.indiatimes.com

    Laurus Labs receives licence from DRDO to manufacture and market COVID drug 2DG

    2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.

  • Sensex, Nifty flat dragged by bank stocks: Key factors keeping market subdued
    economictimes.indiatimes.com

    Sensex, Nifty flat dragged by bank stocks: Key factors keeping market subdued

    As the indices have been hovering around all-time high levels, many quarters of investors find valuation too stretched to buy. Some of them have started piling cash, anticipating a correction.

  • Taking Stock: Market fails to hold record high with Nifty below 15,850. PSU banks stand out
    moneycontrol.com

    Taking Stock: Market fails to hold record high with Nifty below 15,850. PSU banks stand out

    More than 400 stocks, including Tata Consumer Products, Nelco, Laurus Labs and Shree Renuka Sugars, hit a fresh 52-week high on the BSE

  • D-Street Buzz: Nifty Metal outperforms as Tata Steel, SAIL, Vedanta jump 4% each
    moneycontrol.com

    D-Street Buzz: Nifty Metal outperforms as Tata Steel, SAIL, Vedanta jump 4% each

    The metal index jumped close to 3 percent led by Tata Steel and SAIL which jumped over 4 percent each followed by NALCO, JSW Steel, Vedanta, Hindustan Copper and Hindalco Industries among others.

  • Laurus Labs rallies 5% on credit rating upgrade; stock hits record high
    business-standard.com

    Laurus Labs rallies 5% on credit rating upgrade; stock hits record high

    Read more about Laurus Labs rallies 5% on credit rating upgrade; stock hits record high on Business Standard. The company is looking to build new capacities/facilities that would propel its growth in the coming years

  • Hydroxychloroquine Market Size Worth $ 3,784 Million by 2027 at 28% CAGR – Report by Market Research Future (MRFR)
    globenewswire.com

    Hydroxychloroquine Market Size Worth $ 3,784 Million by 2027 at 28% CAGR – Report by Market Research Future (MRFR)

    Hydroxychloroquine Market Insights and Industry Analysis by Strength (200mg, 400mg), by Application (Malaria, COVID-19, Rheumatoid Arthritis), by Region…

Schreibe einen Kommentar

Wenn du schon einen Account hast, logge dich ein bevor du den Kommentar absendest.

Galue Account Vorteile
  • Battles

    Messe dich mit der Community in Battles.

  • Badges

    Erhalte Belohnungen für Kommentare, die der Community helfen.

  • Mehr Informationen für alle

    Poste Bilder oder Videos zu Themen und Unternehmen und helf dabei, dass Investoren ein kontroverseres Bild erhalten.

  • Kein Datenrisiko

    Du kannst jederzeit deinen Account löschen und gespeicherte Daten einsehen.

Dir gefallen die Informationen zu Laurus Labs Limited?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:

Zu Trade Republic

Dir gefallen die Informationen zu Laurus Labs Limited?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:

Zur Comdirect

Dir gefallen die Informationen zu Laurus Labs Limited?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:

Zu BUX Zero

Dir gefallen die Informationen zu Laurus Labs Limited?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:

Zur ING Diba